PeproMene Bio, Inc.

Novel BAFF-R CAR-T Therapy Achieves Complete Response in Heavily Pretreated Follicular Lymphoma Patient

4 days ago

• PeproMene Bio's first-in-class BAFF-R targeted CAR-T cell therapy (PMB-CT01) has achieved complete remission in a heavily pretreated follicular lymphoma patient who had failed seven prior therapies including CD19 CAR-T. • All seven patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with PMB-CT01 have achieved complete responses lasting from 1 to 29+ months, with minimal toxicity reported. • PMB-CT01 targets the BAFF receptor, which is crucial for B-cell survival, potentially making it harder for tumor cells to escape therapy through antigen loss compared to CD19-targeted approaches.

PeproMene Bio Secures $11 Million Investment to Advance BAFF-R CAR T-Cell Therapy for Follicular Lymphoma

5 months ago

• PeproMene Bio has received an $11 million investment from the Institute for Follicular Lymphoma Innovation to develop PMB-CT01, a novel BAFF-R CAR T-cell therapy for relapsed/refractory follicular lymphoma. • Early clinical results show promising efficacy with a 100% complete response rate in six non-Hodgkin lymphoma patients and minimal side effects, including in patients who relapsed after CD19 CAR T-cell therapy. • PMB-CT01 targets the BAFF-R receptor, which is crucial for B-cell survival, potentially making it difficult for tumor cells to escape therapy through antigen loss, a common limitation of current CD19-targeted therapies.

PeproMene Bio's BAFFR-CAR T Cell Therapy Shows Promise in Relapsed B-ALL Trial

a year ago

• PeproMene Bio reports complete remission in the first patient treated with PMB-CT01 (BAFFR-CAR T cells) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). • The Phase 1 trial at City of Hope showed minimal toxicity, with only low-grade cytokine release syndrome that resolved without intervention. • The patient, with CD19- and CD22-negative relapsed B-ALL, had limited therapeutic options prior to receiving PMB-CT01. • PMB-CT01, a first-in-class BAFFR-targeted CAR T-cell therapy, demonstrates potential in overcoming B-cell malignancies, supported by preclinical data.